Cure8 research brief
Cure8 research brief
Krill oil improved colitis signs and intestinal barrier markers in a mouse model and changed colon gene expression linked to cell adhesion—findings that may interest people tracking dietary or supplemental approaches for gut inflammation research.
The study is preclinical: it suggests biological plausibility but not proven benefit or safety in people with IBD.
Researchers in IBD preclinical therapeutics and intestinal biology; clinicians and patients following dietary-supplement research for gut inflammation.
This animal study tested krill oil (KO) alone and combined with dexamethasone (DEX) in a spontaneous chronic colitis mouse model.
KO reduced disease severity, improved epithelial barrier integrity, and altered colonic gene expression linked to tight junctions and cell adhesion molecules; some benefits were similar to DEX and were enhanced when KO was combined with DEX.
The results come from a preclinical mouse model (Winnie mice) and report molecular changes (transcriptomics) in colon tissue rather than clinical outcomes in people. Measures included disease activity, histology, colonic permeability, protein expression of tight junctions, and RNA changes in barrier and cell-adhesion genes.
This work suggests KO has biological effects relevant to intestinal barrier function and immune cell recruitment in this model, supporting further research. It does not establish safety or efficacy in humans, dosing, or interactions with steroids.
Animal-model (mouse) study with transcriptomic analyses; results do not equal clinical evidence. Dosing, safety, and human effectiveness are unknown.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.